Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report

Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report

BackgroundMetastatic colorectal cancer is one of the most common causes of cancer death worldwide. RAS and BRAF mutational analyses are strongly recommended before beginning chemotherapy in the metastatic setting for their predictive role for the efficacy of anti-EGFR monoclonal antibodies. In most...

Full description

Bibliographic Details
Main Authors: Alfonso De Stefano, Nicoletta Zanaletti, Antonino Cassata, Lucrezia Silvestro, Anna Nappi, Rossana Casaretti, Carmela Romano, Francesca Foschini, Claudia Cardone, Marco Borrelli, Antonella Petrillo, Alfredo Budillon, Paolo Delrio, Antonio Avallone
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
case report
anti-EGFR
resistance
intermittent strategy
RAS
BRAF
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1084681/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1084681/full

Similar Items